SURMOUNT trial programme: difference between revisions
Diff·revision 11 → 12·08:48, 8 Jan 2025
Difference between revision 11 and revision 12 of SURMOUNT trial programme. 6 lines changed; the page grew by 133 bytes.
| Revision 11 — 11:36, 14 Dec 2024 SurpassSunniva (talk) add the missing-data handling method 3,137 bytes +435 | Revision 12 — 08:48, 8 Jan 2025 CommaCarys (talk) copyedit 3,270 bytes +133 | ||
|---|---|---|---|
| 37 | <ref name="garvey2023">Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." ''The Lancet'' 402(10402):613–626 (2023). PMID 37385275.</ref> | 37 | <ref name="garvey2023">Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." ''The Lancet'' 402(10402):613–626 (2023). PMID 37385275.</ref> |
| 38 | 38 | ||
| + | 39 | == See also == | |
| + | 40 | * [[Tirzepatide]] | |
| + | 41 | * [[SURPASS trial programme]] | |
| + | 42 | * [[STEP trial programme]] | |
| + | 43 | * [[Weight regain after discontinuation]] | |
| + | 44 | ||
| 39 | {{DEFAULTSORT:SURMOUNT trial programme}} | 45 | {{DEFAULTSORT:SURMOUNT trial programme}} |
| 40 | [[Category:Clinical trial programmes]] | 46 | [[Category:Clinical trial programmes]] |